GleamWall
中文EN

NKTX Nkarta, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1787400 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-25.7%
TTM EPS YoY-25.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-46.6%
ROA-35.1%
ROIC (approx.)-50.0%
Asset turnover—

Leverage & solvency

Liabilities / assets30.1%
Debt / equity0.00x
Current ratio5.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$29.46M$29.05M$24.99M$25.28M$20.20M$20.78M$24.17M$23.13M
SG&A expense$6.31M$14.08M$5.89M$5.68M$7.09M$6.41M$12.39M$7.80M
Operating income-$35.78M-$43.13M-$30.88M-$30.96M-$27.29M-$27.19M-$36.56M-$30.92M
Income tax$0$0$0$0$0$0$0$0
Net income-$33.33M-$40.37M-$27.83M-$27.41M-$21.71M-$22.98M-$31.98M-$25.93M
EBITDA-$33.68M-$40.43M-$28.58M-$28.66M-$24.99M-$24.89M-$34.26M-$28.62M
EPS (basic)-0.45-0.54-0.37—-0.29-0.31-0.43—
EPS (diluted)-0.45-0.54-0.37—-0.29-0.31-0.43—
Weighted avg. shares (diluted)74.64M74.49M74.26M—74.02M73.98M73.92M—
Balance sheet
Cash & equivalents$48.35M$24.96M$27.36M$39.63M$60.11M$53.41M$52.60M$27.87M
Short-term investments$108.25M$157.81M$203.07M$236.65M$222.22M$236.27M$212.91M$239.48M
Current assets$162.55M$188.04M$235.88M$282.51M$289.27M$296.57M$271.55M$273.34M
PP&E, net$54.59M$56.77M$64.42M$66.72M$64.42M$70.34M$72.62M$74.66M
Total assets$308.46M$337.64M$372.07M$404.21M$427.24M$448.31M$470.61M$501.20M
Current liabilities$28.07M$23.56M$18.21M$22.27M$18.99M$18.93M$18.76M$18.92M
Total liabilities$92.71M$89.91M$86.21M$91.88M$89.34M$90.64M$91.80M$93.23M
Shareholders' equity$215.75M$247.74M$285.86M$312.32M$337.90M$357.67M$378.81M$407.98M
Shares outstanding———71.08M———70.65M
Cash flow statement
Operating cash flow-$25.84M-$24.22M-$28.20M-$21.65M-$18.69M-$18.75M-$29.61M-$24.75M
Capital expenditure$1.25M$183,000$413,000$560,000-$8,000$138,000$518,000$1.10M
Free cash flow-$27.08M-$24.41M-$28.61M-$22.21M-$18.68M-$18.89M-$30.13M-$25.85M
Investing cash flow$49.09M$21.15M$15.91M$1.10M$25.39M$19.49M$54.34M-$4.52M
Financing cash flow$143,000$676,000$6,000$64,000$0$77,000$0$184,000
Depreciation & amortization$2.10M$2.70M$2.30M$2.30M$2.30M$2.30M$2.30M$2.30M
Stock-based compensation$1.76M$1.86M$1.90M$1.90M$1.77M$2.05M$2.83M$3.89M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.